Translational Development Acquisition Corp.
TDAC
$10.72
$0.010.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.51% | 378.96% | 67.20% | 56.78% | 11.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.51% | 378.96% | 67.20% | 56.78% | 11.96% |
| Operating Income | -61.51% | -378.96% | -67.20% | -56.78% | -11.96% |
| Income Before Tax | 339.92% | 8,961.28% | 968.97% | 723.89% | 390.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 339.92% | 8,961.28% | 968.97% | 723.89% | 390.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 339.92% | 8,961.28% | 968.97% | 723.89% | 390.74% |
| EBIT | -61.51% | -378.96% | -67.20% | -56.78% | -11.96% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 68.85% | 3,245.93% | 445.27% | 412.73% | 351.38% |
| Normalized Basic EPS | 67.07% | 3,199.07% | 444.92% | 412.37% | 351.07% |
| EPS Diluted | 68.85% | 3,245.93% | 445.27% | 412.73% | 351.38% |
| Normalized Diluted EPS | 67.07% | 3,199.07% | 444.92% | 412.37% | 351.07% |
| Average Basic Shares Outstanding | 287.18% | 300.57% | 232.67% | 122.44% | 12.21% |
| Average Diluted Shares Outstanding | 287.18% | 300.57% | 232.67% | 122.44% | 12.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |